Improved Diagnostic and Prognostic Tools for Rheumatoid Arthritis: Unmet Needs in a Changing MarketDecision ResourcesMarch 21, 2005 19 Pages - SKU: DECR1186941 |
|
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
4/30/2012 | published by: GBI Research
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments Summary GBI Research, the leading business intelligence provider, has released its latest
|
more...
|
$3,500.00
|
|
Celiac Disease - Pipeline Assessment and Market Forecasts to 2019
12/5/2011 | published by: GlobalData
Celiac Disease - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, “Celiac Disease - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source
|
more...
|
$3,500.00
|
|
Liver Disease Treatments: The Global Market
1/1/2012 | published by: BCC Research
In 2009, the global market for drugs used to treat liver disease was worth approximately $12.4 billion. Sales in 2010 decreased and the market did not see much progress, causing overall global sales to remain
|
more...
|
$4,850.00
|
|
Systemic Lupus Erythematosus – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Systemic Lupus Erythematosus – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Systemic Lupus Erythematosus - Pipeline Review, H1 2012', provides an overview of the Systemic Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic
|
more...
|
$500.00
|
|
Rheumatoid Arthritis – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Rheumatoid Arthritis – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Rheumatoid Arthritis - Pipeline Review, H1 2012', provides an overview of the Rheumatoid Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid
|
more...
|
$500.00
|
|
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
12/1/2011 | published by: GBI Research
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market Summary GBI Research, the leading business intelligence provider, has released its latest research “Monoclonal
|
more...
|
$3,500.00
|
|
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
2/14/2012 | published by: GBI Research
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success Summary GBI Research, the leading business intelligence provider, has released its latest research, “Endpoints - Clinical Trials
|
more...
|
$3,500.00
|
|
Psoriasis – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Psoriasis – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Psoriasis - Pipeline Review, H1 2012', provides an overview of the Psoriasis therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest
|
more...
|
$500.00
|
|
Rheumatoid Arthritis Market Forecast
9/8/2011 | published by: Datamonitor
The launch of novel oral drugs and reformulations of current brands are expected to fuel growth across the seven major markets, rising from $12bn in 2010 to $18bn by 2020. TNF inhibitors will remain dominant
|
more...
|
$15,200.00
|
|
Rheumatoid Arthritis Market Forecast
9/8/2011 | published by: Datamonitor
This interactive model includes 2010-20 patient-numbers and sales forecasts for traditional and biologic disease-modifying drugs in the seven major markets (the US, Japan, France, Germany, Italy, Spain and the UK). Introduction The launch of novel oral drugs
|
more...
|
$15,200.00
|
Related Markets
Rheumatology/Arthritis Reports
- China Rheumatoid Arthritis Prescription Drug Sales Data 2006-2010
- Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Market and Product Forecasts: Disease Modification in Rheumatoid Arthritis – Novel therapies plus reformulations poised to enter the market
- Rheumatoid Arthritis Market Forecast
- Market and Product Forecasts: Disease Modification in Rheumatoid Arthritis - Novel therapies plus reformulations poised to enter the market
